Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer

Benedito A. Carneiro, Ramesh K. Ramanathan, Marwan G. Fakih, Smitha S. Krishnamurthi, Barry C. Lembersky, Ronald G. Stoller, Stewart L. Lancaster, Richard A. Pinkerton, Theodore L. Crandall, Amy R. Schmotzer, Douglas M. Potter, Nathan Bahary*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Irinotecan and weekly cetuximab (I+C) is a standard second-line regimen for metastatic colorectal cancer (mCRC). This phase II study investigated the efficacy of every 2 weeks (q2wks) I+C in 31 patients with mCRC. The RR (primary outcome) and time to progression were lower than expected possibly reflecting the reduced dose intensity due to toxicities. TheOSwas consistent with previous publications, however the efficacy of q2wksC+I was not demonstrated. Background: Irinotecan and weekly cetuximab (I+C) is a standard second-line regimen for metastatic colorectal cancer (mCRC). This study investigated the safety and efficacy of every 2 weeks I+C in patients with mCRC. Patients and Methods: Patients with mCRC refractory to first-line fluoropyrimidine/oxaliplatin regimens and not previously treated with I+C were eligible. Response rate (RR) was the primary endpoint. Cetuximab 500 mg/m2 and irinotecan 180 mg/m2 were administered intravenously (I.V.) on day 1 every 2 weeks. Results: Patient characteristics (n = 31): male (n = 17), median age 62; Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤1 (n = 30), and PS = 2 (n = 1). Median number of cycles = 3 (range, 1-22). I+C doses were modified in 18 and 12 patients, respectively. Grade 3/4 ad verseevents: acneiform rash (n=6); neutropenia (n=6); and diarrhea (n=5); there was one grade 5 respiratory failure, possibly related to therapy. Two patients had a partial response, 11 had stable disease, and 18 had progressive disease resulting in an overall RR of 6% and disease control rate of 41.9%. Median overall survival (OS) was 9.3 months (95% CI, 5.1-15), and time to progression (TTP) was 2.4 months (95% CI, 1.3-4.6). K-ras and BRAF mutations were detected in 39% and 9%, respectively, of the patients tested. There was a trend toward longer TTP among patients with wild-type K-ras and BRAF (2.6 vs. 1.7 months; P = 0.16), and OS was significantly longer in those patients (14.1 vs. 5.5 months; P = 0.04). Conclusions: The RR and TTP were lower than expected and may reflect the reduced dose intensity due to toxicities. While the OS was consistent with previous publications, the efficacy of this combination was not demonstrated.

Original languageEnglish (US)
Pages (from-to)53-59
Number of pages7
JournalClinical colorectal cancer
Volume11
Issue number1
DOIs
StatePublished - Jan 1 2012

Keywords

  • Biweekly
  • Cetuximab
  • EGFR
  • Irinotecan

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer'. Together they form a unique fingerprint.

Cite this